Metastatic Prostate Cancer (mCRPC)
Oncology·MeSH: Prostatic Neoplasms
Prevalence
143.5 / 100K
Incidence
18.4 / 100K/yr
2 drugs in development·1 company·1 clinical trial
Drug Pipeline by Phase
Phase 2(1)
| Drug | Company |
|---|---|
| JSB462 | Novartis AG (NVS) |
Phase 1(1)
| Drug | Company |
|---|---|
| jsb462 | Novartis AG (NVS) |
Frequently asked questions
How many drugs are in development for Metastatic Prostate Cancer (mCRPC)?
BioSniper tracks 2 drugs in development for Metastatic Prostate Cancer (mCRPC) across 1 company.
How many clinical trials target Metastatic Prostate Cancer (mCRPC)?
There are 1 clinical trial targeting Metastatic Prostate Cancer (mCRPC) tracked by BioSniper.
What is the prevalence of Metastatic Prostate Cancer (mCRPC)?
The estimated prevalence of Metastatic Prostate Cancer (mCRPC) is approximately 143.5 per 100,000 population.
Deep-dive into Metastatic Prostate Cancer (mCRPC)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis